Galvanize Therapeutics, Inc. filed a Form D with the SEC, reporting $136.2M sold, of a $136.2M offering.
What happened
Galvanize Therapeutics develops pulsed electric field (PEF) energy devices for soft tissue ablation and endoscopic care, including the Aliya and RheOx systems. This Form D reports a cash raise of $136,185,232, which signals substantial capital available to support commercialization and makes the company relevant to vendors serving medtech growth.
Source
Extracted by Autobound
From the Signal API record- Signal
- Form D offering
What this signalsNew funding often brings new budget and vendor reviews.
- Amount
- $136M
- Industry group
- Biotechnology
- Headquarters
- Redwood City, CA
- Location
- REDWOOD CITY, CALIFORNIA
- Filed
- Nov 18, 2026
- Jurisdiction
- Delaware
More from Galvanize Therapeutics, Inc.
More form D offering signals at other companies
- Form D offeringRising Tide Dental Holdings, LLCRising Tide Dental Holdings, LLC filed a Form D with the SEC, reporting $61.7M sold, of a $61.7M offering.Form D offering
- Form D offeringAnsa Biotechnologies, Inc.Ansa Biotechnologies, Inc. filed a Form D with the SEC, reporting $54.4M sold, of a $71.9M offering.Form D offering
- Form D offeringNexus Networks, Inc.Nexus Networks, Inc. filed a Form D with the SEC, reporting $47.1M sold, of a $47.5M offering.Form D offering
The full record
From the Signal API recordPeople
- Doug GodshallExecutive Officer, Director · Named in the filing
- Seth HarrisonDirector · Named in the filing
- Antoine PapiernikDirector · Named in the filing
- Zack ScottDirector · Named in the filing
- David LewisDirector · Named in the filing
- Steve AnheierExecutive Officer · Named in the filing
- Isaac ZachariasDirector · Named in the filing
- Laura FrancisDirector · Named in the filing
Numbers
- Amount (USD)
- $136M
- Investors
- 26
Details
- CIK
- 0001659073
- Website
- galvanizetx.com
- Form
- D
- Entity type
- Corporation
- Primary topic
- Biotech/MedTech Growth
- Revenue range
- Decline to Disclose
- Business state
- CA
- Accession number
- 0001659073-26-000004
- Resolved entity type
- Operating company
- Has non accredited investors
- No
- Filer
- Galvanize Therapeutics, Inc.
Topics and mentions
Topics
- Biotechnology
- Medical Devices
- Commercialization
- Clinical Evidence
- Growth Capital
Exemptions
- 06b
Securities
- Equity
Extraction
- Confidence
- High
- Relevance
- 80%
- Detected
- Nov 18, 2026
- signal_type
sec-form-d-funding- signal_subtype
newFilingCompany
Use this data
Get every form D offering signal for Galvanize Therapeutics, Inc. and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Galvanize Therapeutics, Inc. this week?”
Send it to your own tools
The Signal API returns form D offering signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-form-d-funding record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/fd-0001659073-26-000004 returns this record as JSON. POST /v1/companies/enrich returns every signal for galvanizetx.com.
{
"signal_id": "fd-0001659073-26-000004",
"signal_type": "sec-form-d-funding",
"signal_subtype": "newFilingCompany",
"detected_at": "2026-11-18T00:00:00+00:00",
"company": {
"name": "Galvanize Therapeutics, Inc.",
"domain": "galvanizetx.com"
},
"data": {
"cik": "0001659073",
"phone": "650-268-4252",
"detail": "The filing suggests a growth-stage biotechnology company moving from clinical adoption into broader commercial execution, with spend likely flowing toward product development, regulatory work, clinical evidence, manufacturing, and market expansion. Vendors should pay attention to opportunities around device manufacturing, quality systems, clinical operations, hospital sales enablement, and go-to-market infrastructure as the company scales deployment across providers.",
"topics": [
"Biotechnology",
"Medical Devices",
"Commercialization",
"Clinical Evidence",
"Growth Capital"
],
"summary": "Galvanize Therapeutics develops pulsed electric field (PEF) energy devices for soft tissue ablation and endoscopic care, including the Aliya and RheOx systems. This Form D reports a cash raise of $136,185,232, which signals substantial capital available to support commercialization and makes the company relevant to vendors serving medtech growth.",
"website": "https://galvanizetx.com",
"location": "REDWOOD CITY, CALIFORNIA",
"file_date": "2026-11-18",
"form_type": "D",
"relevance": 0.8,
"confidence": "high",
"exemptions": [
"06b"
],
"filing_url": "https://www.sec.gov/Archives/edgar/data/1659073/000165907326000004/",
"source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001659073&type=D&dateb=&owner=include&count=40",
"entity_name": "Galvanize Therapeutics, Inc.",
"entity_type": "Corporation",
"jurisdiction": "DELAWARE",
"primary_topic": "Biotech/MedTech Growth",
"revenue_range": "Decline to Disclose",
"business_state": "CA",
"industry_group": "Biotechnology",
"related_persons": [
{
"name": "Doug Godshall",
"roles": [
"Executive Officer",
"Director"
]
},
{
"name": "Seth Harrison",
"roles": [
"Director"
]
},
{
"name": "Antoine Papiernik",
"roles": [
"Director"
]
},
{
"name": "Zack Scott",
"roles": [
"Director"
]
},
{
"name": "David Lewis",
"roles": [
"Director"
]
},
{
"name": "Steve Anheier",
"roles": [
"Executive Officer"
]
},
{
"name": "Isaac Zacharias",
"roles": [
"Director"
]
},
{
"name": "Laura Francis",
"roles": [
"Director"
]
}
],
"total_investors": 26,
"accession_number": "0001659073-26-000004",
"securities_types": [
"Equity"
],
"business_location": "Redwood City, CA",
"total_amount_sold": 136185232,
"resolved_entity_name": "Galvanize Therapeutics, Inc.",
"resolved_entity_type": "operating_company",
"total_offering_amount": 136185232,
"company_domain_confidence": 10,
"has_non_accredited_investors": false
}
}
curl https://signals.autobound.ai/v1/signals/fd-0001659073-26-000004 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"galvanizetx.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.